Resultados de la búsqueda 11-20 of 14847 for Tyrosine

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

2. Esclerosis múltiple

   Bruton tyrosine kinase inhibitors for multiple sclerosis. Nature Reviews Neurology. 2023; doi:10.1038/s41582-023-00800-7. Pediatric MS. National Multiple ...

3. Enfermedad de Wilson

   Biochemical, enzymatic, and computational characterization of recurrent somatic mutations of the human protein tyrosine phosphatase PTP1B in primary mediastinal ...

4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) ... The Standard of Care options are: an EGFR tyrosine kinase inhibitor ...

5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus ...

6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus ...

7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus ...

8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

9. Hematología - Ensayos clínicos - Mayo Clinic

   This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

10. Hematología - Ensayos clínicos

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...